Cite
HARVARD Citation
Cardone, C. et al. (2020). AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European journal of cancer. pp. 1-10. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Cardone, C. et al. (2020). AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European journal of cancer. pp. 1-10. [Online].